---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-21-000041"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:25:01.642605+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint

## Summary
- Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).
- Net loss per share $0.36; adjusted loss per share $0.30; adjusted EBITDA loss $2.7M.
- FY2021 revenue guidance raised to $270-275M (growth ~31-33%); adjusted loss per share guidance ~$1.20.
- aMAZE trial failed primary efficacy endpoint; safety endpoint met. Potential material adjustments expected in H2 2021.

## SEC filing metadata
- accession: 0001323885-21-000041
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388521000041/0001323885-21-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388521000041/atrc-20210804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-21-000041
- JSON: https://secwatch.observer/filing/0001323885-21-000041.json
- Plain text: https://secwatch.observer/filing/0001323885-21-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.